Managing the risk of drug-induced liver injury.
In clinical trials, bosentan was shown to cause significant drug-induced liver injury (DILI) in some patients. Because it is not possible to identify those at higher risk for DILI, all patients to be treated with bosentan must enroll in a program requiring documentation of liver blood testing before they can receive the drug. Because this program is costly and is perceived as onerous, a genetic test capable of identifying susceptible individuals would probably be rapidly adopted by physicians.
1] Hamner-University of North Carolina Institute for Drug Safety Sciences and Department of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA [2] Department of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
P B
PB
Watkins
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077300:Bosentan; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D065729:Cytochrome P-450 CYP2C9; D065128:Endothelin Receptor Antagonists; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D013449:Sulfonamides / Q000009:adverse effects*
D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D000077300:Bosentan